After Abeta Blow, Biogen And Eisai Get BACE Boost

Elenbecestat can continue in the Phase III MISSION AD studies in Alzheimer’s, the data safety monitoring board says.

Caution
BACE inhibitors have not fared well in the clinic

Eisai Co. Ltd. and Biogen Inc. should continue with their Phase III trial of elenbecestat in early Alzheimer’s disease, according to the data safety and monitoring board for the program. The DSMB recommendation came after a review of safety data, including the potential for decline in cognition.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Neurological

More from Therapy Areas